• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Jan De Witte joins GHO Capital as Operating Partner

    2/11/25 4:30:00 AM ET
    $IART
    $RMD
    Medical/Dental Instruments
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $IART alert in real time by email

    Jan De Witte joins GHO Capital as Operating Partner

    Former CEO of Integra LifeSciences with significant strategic and operational experience to support GHO Capital's portfolio

    London, UK – 11 February 2025: Global Healthcare Opportunities, or GHO Capital Partners LLP ("GHO"), the European specialist investor in global healthcare, is pleased to announce the appointment of Jan De Witte as Operating Partner.

    Jan is an accomplished senior executive with extensive experience leading international growth and transformation for global technology and life sciences companies. Prior to joining GHO, he was Chief Executive Officer and member of the Board of Directors at Integra LifeSciences (("Integra", NASDAQ:IART), a global leader in regenerative tissue technologies, and neurosurgical and ENT solutions. At Integra Jan drove international expansion and operational excellence, and through strategic acquisitions and innovation added $1 billion to the total addressable market of the company's offerings.

    Prior to Integra, Jan served as CEO of Barco N.V. (EBR: BAR), directing the advanced visualisation technology company's digital transformation and global market expansion. He strengthened Barco's position in the healthcare, entertainment, and enterprise sectors through new product launches and operational improvements and global market expansions. Earlier in his career, he spent 18 years at GE Healthcare leading global teams in Digital Health, Services, Manufacturing, Quality and Supply Chain across the Americas, EMEA, and Asia. Jan's career started with foundational roles in Operations at Procter & Gamble and as Senior Consultant at McKinsey in Europe.

    Jan currently serves as a Director of ResMed Inc. (NYSE:RMD), a digital health and medical device leader. His board experience includes previous roles at Barco N.V. and international joint ventures. He holds an M.B.A. from Harvard Business School and Master's and Bachelor's degrees in electromechanical engineering with highest distinction from KU Leuven, Belgium.

    As Operating Partner, Jan will leverage his extensive leadership experience and global network to support and grow GHO's portfolio companies, as well as supporting with the firm's transatlantic deal origination.

    The Partners at GHO Capital commented: "Jan brings a wealth of healthcare industry expertise and a strong track record to our team as we look to implement our proven operational playbook and drive expansion and growth across our portfolio. The healthcare sector is experiencing significant innovation, supported by favourable market conditions, and Jan's experience will help us identify businesses with the most substantial growth potential. On behalf of the entire GHO team, we warmly welcome him and look forward to the positive impact he will make."

    Commenting on his new appointment, Jan De Witte, Operating Partner at GHO Capital, said: "My focus throughout my career has always been to support innovative healthcare companies as they grow and transform, whilst creating long-term investor value. I am excited to be joining GHO Capital, one of Europe's leading healthcare specialist private equity firms, who are committed to driving the highest standards across the healthcare sector. I look forward to working with the team and leveraging my expertise to support GHO's portfolio companies realise their full potential."

    -Ends-

    Further information:

    GHO Capital Partners LLP

    T +44 20 3700 7440

    E IR@ghocapital.com

    For Media Enquiries



    ICR Healthcare



    Amber Fennell, Angela Gray, Kris Lam











    Tel: +44 (0) 20 3709 5700



    ghocapital@icrhealthcare.com







    About GHO Capital

    Global Healthcare Opportunities, or GHO Capital Partners LLP, is a leading specialist healthcare investment advisor based in London. GHO Capital applies global capabilities and perspectives to unlock high growth healthcare opportunities, targeting Pan-European and transatlantic internationalisation to build market leading businesses of strategic global value. GHO Capital's proven investment track record reflects the unrivalled depth of our industry expertise and network. GHO Capital partners with strong management teams to generate long-term sustainable value, improving the efficiency of healthcare delivery to enable better, faster, more accessible healthcare. For further information, please visit www.ghocapital.com.



    Primary Logo

    Get the next $IART alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IART
    $RMD

    CompanyDatePrice TargetRatingAnalyst
    Integra LifeSciences Holdings Corporation
    $IART
    5/28/2026$16.00Sell → Neutral
    Citigroup
    ResMed Inc.
    $RMD
    4/15/2026Overweight
    Analyst
    Integra LifeSciences Holdings Corporation
    $IART
    4/15/2026Buy → Hold
    Argus
    ResMed Inc.
    $RMD
    12/16/2025$275.00Outperform → Neutral
    Robert W. Baird
    ResMed Inc.
    $RMD
    9/18/2025$330.00Buy
    Citigroup
    ResMed Inc.
    $RMD
    9/2/2025Hold → Outperform
    CLSA
    ResMed Inc.
    $RMD
    7/16/2025$294.00Sector Perform → Outperform
    RBC Capital Mkts
    ResMed Inc.
    $RMD
    7/15/2025$294.00Sector Perform → Outperform
    RBC Capital Mkts
    More analyst ratings

    $IART
    $RMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by EVP & Chief Commercial Officer Mcbreen Michael J.

    4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)

    6/3/26 4:58:41 PM ET
    $IART
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by President and CEO Essig Stuart

    4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)

    6/3/26 4:54:58 PM ET
    $IART
    Medical/Dental Instruments
    Health Care

    Global General Counsel Rider Michael J covered exercise/tax liability with 269 units of ResMed Common Stock, decreasing direct ownership by 3% to 9,488 units (SEC Form 4) (tax withholding)

    4 - RESMED INC (0000943819) (Issuer)

    6/3/26 3:45:27 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    $IART
    $RMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Angelini Ventures Marks First Portfolio Company Exit as ResMed Acquires Noctrix Health for $340 million

    Noctrix Health acquisition validates Angelini Ventures' strategy of investing in innovative healthcare companies addressing significant unmet medical needs and advancing connected health Rome, Italy, 3rd June 2026 – Angelini Ventures, the corporate venture firm of Angelini Industries focused on investing in companies developing innovative solutions in BioTech and HealthTech, announces that portfolio company Noctrix Health has been acquired by ResMed (NYSE:RMD), a global leader in sleep health and respiratory care, in a transaction valued at $340 million. The transaction further strengthens Angelini Ventures' mission to support the next generation of healthcare innovators, combining capit

    6/3/26 7:40:36 AM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    The Body as Blueprint: A Recently Public Biotech Bets That Regrown Tissue Beats Replacement Parts

    Issued on behalf of Conexeu Sciences Inc.A newly listed regenerative-tissue company has put its lead breast-reconstruction matrix on the bench at one of the world's largest bioprinting institutes. For investors tracking the space, the partner it chose may matter more than anything it has said.Equity Insider Market CommentaryTAMPA, Fla., June 2, 2026 /CNW/ -- For more than half a century, the answer to lost tissue has been to manufacture a substitute and put it where the tissue used to be. Replace, don't restore. That logic built the modern implant industry, and it works — up to a point. But it leaves a gap, and the gap shows up in the numbers: roughly two-thirds of the more than 100,000 wome

    6/2/26 9:00:00 AM ET
    $BVS
    $IART
    $MDXG
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Integra LifeSciences to Present at the 2026 Jefferies Global Healthcare Conference

    PRINCETON, N.J., June 02, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced that chief financial officer Lea Knight will present at the 2026 Jefferies Global Healthcare Conference on June 3, 2026 at 10:30am ET. A live webcast of the presentation will be available on the Integra LifeSciences investor relations website under EVENTS & PRESENTATIONS. About Integra LifeSciencesIntegra LifeSciences (NASDAQ:IART) is a global medical technology leader dedicated to restoring lives. We are advancing transformational care through impactful innovation in neurosurgery and tissue reconstruction, specialized fi

    6/2/26 7:30:00 AM ET
    $IART
    Medical/Dental Instruments
    Health Care

    $IART
    $RMD
    SEC Filings

    View All

    SEC Form SD filed by Integra LifeSciences Holdings Corporation

    SD - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Filer)

    5/29/26 4:42:09 PM ET
    $IART
    Medical/Dental Instruments
    Health Care

    SEC Form SD filed by ResMed Inc.

    SD - RESMED INC (0000943819) (Filer)

    5/26/26 4:30:09 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    SEC Form S-8 filed by Integra LifeSciences Holdings Corporation

    S-8 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Filer)

    5/8/26 4:45:24 PM ET
    $IART
    Medical/Dental Instruments
    Health Care

    $IART
    $RMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Integra upgraded by Citigroup with a new price target

    Citigroup upgraded Integra from Sell to Neutral and set a new price target of $16.00

    5/28/26 8:44:41 AM ET
    $IART
    Medical/Dental Instruments
    Health Care

    Analyst initiated coverage on ResMed

    Analyst initiated coverage of ResMed with a rating of Overweight

    4/15/26 11:26:08 AM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    Integra downgraded by Argus

    Argus downgraded Integra from Buy to Hold

    4/15/26 8:07:00 AM ET
    $IART
    Medical/Dental Instruments
    Health Care

    $IART
    $RMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Graves Jeffrey A bought $102,150 worth of shares (9,000 units at $11.35), increasing direct ownership by 28% to 41,086 units (SEC Form 4)

    4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)

    11/6/25 4:05:46 PM ET
    $IART
    Medical/Dental Instruments
    Health Care

    Essig Stuart bought $1,499,979 worth of shares (52,641 units at $28.49), increasing direct ownership by 12% to 487,922 units (SEC Form 4)

    4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)

    5/24/24 4:08:19 PM ET
    $IART
    Medical/Dental Instruments
    Health Care

    Hill Barbara B bought $995,816 worth of shares (36,350 units at $27.40) (SEC Form 4)

    4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)

    5/22/24 4:09:18 PM ET
    $IART
    Medical/Dental Instruments
    Health Care

    $IART
    $RMD
    Leadership Updates

    Live Leadership Updates

    View All

    Resmed Chief Financial Officer Brett Sandercock to Retire; Aaron Bloomer Appointed as Successor

    SAN DIEGO, April 30, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD)), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced that Brett Sandercock, Chief Financial Officer, plans to retire effective May 4, 2026. After conducting a comprehensive search, Aaron Bloomer has been appointed as his successor.  "After 27 years with Resmed, including 20 as CFO, Brett leaves an outstanding legacy of disciplined leadership and trusted partnership," said Mick Farrell, Chairman and CEO of Resmed. "Brett's leadership has helped guide Resmed through significant growth and transformation, while keeping a clear focus on long-term value creat

    4/30/26 4:10:00 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    Neuronetics Appoints Dan Reuvers as President and Chief Executive Officer

    MALVERN, Pa., March 17, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM) (the "Company"), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and the maker of NeuroStar® Advanced Therapy, today announced the appointment of Dan Reuvers as the Company's next President and Chief Executive Officer, effective March 23, 2026. Mr. Reuvers will also join the Board of Directors at that time. He succeeds Keith Sullivan, who will step down as the Company's President and Chief Executive Officer on March 23, 2026 and retire on March 31, 2026 after five and a half years of leadin

    3/17/26 7:45:00 AM ET
    $IART
    $STIM
    $TCMD
    Medical/Dental Instruments
    Health Care

    Integra LifeSciences Announces Key Executive Leadership Appointments

    PRINCETON, N.J., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced the appointment of Teshtar Elavia as corporate vice president and chief technology officer, a newly created position to lead research and development (R&D), including product and technology development, across the company. The company also announced the appointments of Michael Hutchinson as executive vice president, chief legal officer and secretary, and Kerri DiPietro as corporate vice president and chief quality officer. The creation of the chief technology officer (CTO) position underscores Integra's commitment to build

    2/17/26 8:30:00 AM ET
    $IART
    Medical/Dental Instruments
    Health Care

    $IART
    $RMD
    Financials

    Live finance-specific insights

    View All

    Angelini Ventures Marks First Portfolio Company Exit as ResMed Acquires Noctrix Health for $340 million

    Noctrix Health acquisition validates Angelini Ventures' strategy of investing in innovative healthcare companies addressing significant unmet medical needs and advancing connected health Rome, Italy, 3rd June 2026 – Angelini Ventures, the corporate venture firm of Angelini Industries focused on investing in companies developing innovative solutions in BioTech and HealthTech, announces that portfolio company Noctrix Health has been acquired by ResMed (NYSE:RMD), a global leader in sleep health and respiratory care, in a transaction valued at $340 million. The transaction further strengthens Angelini Ventures' mission to support the next generation of healthcare innovators, combining capit

    6/3/26 7:40:36 AM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    Integra LifeSciences Reports First Quarter 2026 Financial Results

    PRINCETON, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today reported financial results for the first quarter ending March 31, 2026. First Quarter 2026 Highlights First quarter revenues of $391.9 million increased 2.4% on a reported basis and 1.3% on an organic basis compared to the prior year. First quarter GAAP earnings per diluted share of $(0.06), compared to $(0.33) in the prior year. Adjusted earnings per diluted share of $0.54, compared to $0.41 in the prior year.Reaffirming 2026 full year revenue guidance of $1.662 billion to $1.702 billion and updating 2026 adjusted earnings

    5/5/26 6:00:00 AM ET
    $IART
    Medical/Dental Instruments
    Health Care

    Integra LifeSciences Announces Leadership Transition

    Stuart Essig Appointed as Integra's Next President and Chief Executive OfficerMichael McBreen Appointed Chief Commercial Officer PRINCETON, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation ("Integra" or the "Company") (NASDAQ:IART), a leading global medical technology company, today announced that Stuart M. Essig, chairman of Integra's Board of Directors (the "Board"), has been appointed president and chief executive officer, effective May 1, 2026. Mr. Essig will continue to serve as chairman. He succeeds Mojdeh Poul who is pursuing other opportunities. The Company also announced that Michael McBreen, currently executive vice president, president, Codman S

    5/5/26 6:00:00 AM ET
    $IART
    Medical/Dental Instruments
    Health Care

    $IART
    $RMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Integra LifeSciences Holdings Corporation

    SC 13G - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Subject)

    11/12/24 5:20:30 PM ET
    $IART
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Integra LifeSciences Holdings Corporation

    SC 13G/A - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Subject)

    11/12/24 12:54:20 PM ET
    $IART
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Integra LifeSciences Holdings Corporation

    SC 13G/A - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Subject)

    8/12/24 10:06:35 AM ET
    $IART
    Medical/Dental Instruments
    Health Care